Tarceva - Erlotinib - Genentech/Osi pharmaceuticals - Tyrosine kinase inhibitor approved for NSCLC

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2004年 / 39卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：568 / 568
页数：1
相关论文
共 50 条
  • [21] Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib
    Wang, Xiaofei
    Chen, Keqiang
    Yu, Ying
    Xiang, Yi
    Kim, Jae Hong
    Gong, Wanghua
    Huang, Jiaqiang
    Shi, Guochao
    Li, Qingyun
    Zhou, Min
    Sayers, Thomas
    Tewary, Poonam
    Gao, Beili
    Wang, Ji Ming
    ONCOTARGET, 2017, 8 (65) : 109068 - 109078
  • [22] Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
    Guttman-Yassky, Emma
    Mita, Alain
    De Jong, Maja
    Matthews, Lesley
    McCarthy, Sean
    Iwata, Kenneth K.
    Verweij, Jaap
    Rowinsky, Eric K.
    Krueger, James G.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) : 2010 - 2019
  • [23] Remission of severe Psoriasis vulgaris under Treatment with the Tyrosine Kinase Inhibitor Erlotinib
    Goepel, L. M.
    Jacobi, A.
    Augustin, M.
    Radtke, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 101 - 101
  • [24] Effects of EGFR Tyrosine Kinase Inhibitor Erlotinib in Prostate Cancer Cells In Vitro
    Festuccia, Claudio
    Gravina, Giovanni Luca
    Biordi, Leda
    D'Ascenzo, Sandra
    Dolo, Vincenza
    Ficorella, Corrado
    Ricevuto, Enrico
    Tombolini, Vincenzo
    PROSTATE, 2009, 69 (14): : 1529 - 1537
  • [25] Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
    Nelson, Valerie
    Ziehr, Jacqueline
    Agulnik, Mark
    Johnson, Melissa
    ONCOTARGETS AND THERAPY, 2013, 6 : 135 - 143
  • [26] Metabolic phenotyping with positron emission tomography for prediction of tumor response to the epidermal growth factor receptor kinase inhibitor erlotinib (tarceva).
    Lee, K. K.
    So, H.
    Hildebrandt, I.
    Wei, L. H.
    Weber, W.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (01) : S93 - S93
  • [27] Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
    Tartarone, Alfredo
    Lazzari, Chiara
    Lerose, Rosa
    Conteduca, Vincenza
    Improta, Giuseppina
    Zupa, Angela
    Bulotta, Alessandra
    Aieta, Michele
    Gregorc, Vanesa
    LUNG CANCER, 2013, 81 (03) : 328 - 336
  • [28] Phase II study of the EGFR tyrosine kinase inhibitor erlotinib (Tarceva) in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma
    Jackman, D
    Lucca, J
    Fidias, R
    Rabin, M
    Lynch, T
    Ostler, P
    Skarin, A
    Temel, J
    Johnson, B
    Janne, P
    LUNG CANCER, 2005, 49 : S62 - S63
  • [29] A review of erlotinib - an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor
    Iyer, Renuka
    Bharthuar, Anubha
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (02) : 311 - 320
  • [30] Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930
    Petti, F
    Thelemann, A
    Kahler, J
    McCormack, S
    Castaldo, L
    Hunt, T
    Nuwaysir, L
    Zeiske, L
    Haack, H
    Sullivan, L
    Garton, A
    Haley, JD
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (08) : 1186 - 1197
12345